14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AVTX vs OTLK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Avalo Therapeutics, Inc. (AVTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). AVTX carries a Unified Composite Score of 54.9/100 (HOLD) at $7.33 (N/M Forward P/E, -161962.7% operating margin), whereas OTLK carries 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin).
Composite vs. Pillar Nuance: While AVTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. OTLK 48.6/100 HOLD), OTLK captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (4781.8% vs. -161962.7% operating margin) and revenue trajectory (-99.4% vs. -69.3% YoY).
Technical & Structure Timing Caution: AVTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile OTLK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $445.2M market capitalization and -161962.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
OTLK Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $107.1M market capitalization and 4781.8% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AVTX vs OTLK Key Questions & Quantitative Answers
As of Nov 16, 2026, Outlook Therapeutics, Inc. (OTLK) is the stronger overall head-to-head candidate over Avalo Therapeutics, Inc. (AVTX) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). AVTX carries a Unified Composite Score of 54.9/100 (HOLD) at $7.33 (N/M Forward P/E, -161962.7% operating margin), whereas OTLK carries 48.6/100 (HOLD) at $0.40 (2.9x Forward P/E, 4781.8% operating margin). Composite vs. Pillar Nuance: While AVTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. OTLK 48.6/100 HOLD), OTLK captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (4781.8% vs. -161962.7% operating margin) and revenue trajectory (-99.4% vs. -69.3% YoY). Technical & Structure Timing Caution: AVTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.0); meanwhile OTLK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AVTX leads the Growth & Scale pillar: AVTX posts -69.3% YoY revenue growth and +0.0% YoY earnings growth on $59,000 TTM revenue (N/A gross margin, -161962.7% operating margin), compared with OTLK at -99.4% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 4781.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AVTX cumulative revenue shifted +100.0% while OTLK shifted N/A. In operating R&D and SG&A reinvestment, AVTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OTLK.
OTLK screens cheaper on headline valuation multiples. AVTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OTLK trades at 2.9x Forward P/E, 2.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVTX (-33.6% ROE) versus OTLK (-3.6% ROE) capital efficiency.
In options market volatility and institutional positioning, AVTX carries 88.7% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 167% Vol realized risk). By comparison, OTLK carries 181.3% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.26x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.47β · 79% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.